My Treatment Approach: HER2+ Breast Cancer - Episode 11

Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions

, ,

Key opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.

EP. 1: The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients
EP. 2: Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape
EP. 3: First-Line HER2+ Metastatic Breast Cancer Trials in Focus
EP. 4: Case Study: Treatment Sequencing for a 62 Year Old Woman with HER2+ Metastatic Breast Cancer After Progression on T-DXd
EP. 5: Evidence-Based Sequencing for HER2+ mBC After Progression: Clinical Trial Data and NCCN Guideline Updates
EP. 6: Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer
EP. 7: TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting
EP. 8: Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches
EP. 9: Exploring the Latest Updates from the HER2CLIMB Trial Evaluating Tucatinib in Patients with Brain Metasteses
EP. 10: Managing Brain Metastases in HER2+ Metastatic Breast Cancer: Clinical Trial Data and Multidisciplinary Approaches
Now Viewing
EP. 11: Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions

Related Content:

My Treatment Approach: HER2+ Breast CancerMemorial Sloan Kettering Cancer Center University of Illinois Cancer CenterBreast CancerInsights
postMONARCH Meets Primary End Point of Improvement of PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression
Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer
Dr Llombart-Cussac on Preventing Neutropenia and Diarrhea in HR+/HER2– Advanced Breast Cancer